ACRV

Acrivon Therapeutics Inc

1.66

Oct 30 • 3:59 PM ET -0.10 (-5.68%)

1.70

Aftermarket • 7:30 PM ET +0.04 (2.41%)

Healthcare Biotechnology USA Micro NASD

Oct 29, 8:06 AMAcrivon Therapeutics reports durable responses and favorable safety for WEE1/PKMYT1 inhibitor ACR-2316 in Phase 1/2 lung cancer trial

Peers: ZNTL APRE IDYA TNGX BDTX OKUR CRDF ERAS MAIA SDGR

| Held by: VTI VXF IWC BUSM DXUV CHNA

Scroll to Statements

Index	-
Market Cap	71.14M
Enterprise Value	-16.70M
Income	-74.22M
Sales	0.00M
Book/sh	2.02
Cash/sh	2.10
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	76
IPO	Nov 15, 2022

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.82
P/C	0.79
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	7.99
Current Ratio	7.99
Debt/Eq	0.02
LT Debt/Eq	0.01
Option/Short	No / Yes

EPS (ttm)	-1.89
EPS next Y	-1.66
EPS next Q	-0.44
EPS this Y	8.42%
EPS next Y	10.50%
EPS next 5Y	14.02%
EPS past 3/5Y	-12.47% -51.39%
Sales past 3/5Y	- -
EPS Y/Y TTM	16.04%
Sales Y/Y TTM	-
EPS Q/Q	21.40%
Sales Q/Q	-
Earnings	Aug 12 AMC
EPS/Sales Surpr.	14.38% -

Insider Own	22.47%
Insider Trans	-0.20%
Inst Own	45.37%
Inst Trans	3.20%
ROA	-57.61%
ROE	-64.63%
ROIC	-84.69%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-7.11%
SMA50	-14.36%
SMA200	-6.11%
Trades

Shs Outstand	42.85M
Shs Float	33.22M
Short Float	5.23%
Short Ratio	5.75
Short Interest	1.74M
52W High	3.56 -53.37%
52W Low	1.27 30.71%
Volatility	7.09% 6.54%
ATR (14)	0.12
RSI (14)	38.83
Beta	1.94
Rel Volume	0.55
Avg Volume	302.04K
Volume	165,749

Perf Week	-4.05%
Perf Month	-17.41%
Perf Quarter	6.41%
Perf Half Y	-20.57%
Perf YTD	-31.12%
Perf Year	-14.43%
Perf 3Y	-68.02%
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	11.50
Prev Close	1.76
Price	1.66
Change %	-5.68%

Consensus

Strong Buy

Avg. Price Target

$11.50

Implied Upside

+592.8%

Analysts10incl. previous ratings

Rating Distribution10 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
May 05, 2025	Resumed	PPiper Sandler	Overweight	$6	+261.4%
Jan 31, 2025	Initiated	KKeyBanc Capital Markets	Overweight
Sep 16, 2024	Upgrade	LLadenburg Thalmann	Neutral → Buy	$16	+863.9%
Apr 29, 2024	Downgrade	LLadenburg Thalmann	Buy → Neutral
Mar 01, 2024	Initiated	JJMP Securities	Mkt Outperform	$14	+743.4%
Dec 15, 2023	Resumed	JJefferies	Buy	$17 → $12	+622.9%
Oct 05, 2023	Initiated	MMaxim Group	Buy
Jun 02, 2023	Initiated	OOppenheimer	Outperform	$25	+1,406.0%
May 08, 2023	Initiated	BBMO Capital Markets	Outperform	$25	+1,406.0%
Apr 27, 2023	Initiated	LLadenburg Thalmann	Buy	$22	+1,225.3%
Apr 20, 2023	Initiated	HH.C. Wainwright	Buy	$24	+1,345.8%
Dec 12, 2022	Initiated	PPiper Sandler	Overweight	$25	+1,406.0%
Dec 12, 2022	Initiated	JJefferies	Buy	$17	+924.1%
Dec 12, 2022	Initiated	CCowen	Outperform

Oct-29-26 08:00AM	Acrivon Announces Late-Breaking Oral Plenary Presentation of Early Phase 1/2 Clinical Results in AP3-Predicted Tumors for its First-in-Class WEE1/PKMYT1 Inhibitor ACR-2316 at the 38th EORTC-NCI-AACR Symposium (GlobeNewswire)
Oct-20-26 08:30AM	Acrivon Advances ACR-7280, an Optimized, AP3-Enabled, Potential First-in-Class, Oral CDK11 Inhibitor Toward IND Filing in First Half of 2027 (GlobeNewswire) +6.21%
Sep-02-26 08:00AM	Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference (GlobeNewswire)
Aug-31-26 08:30AM	Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer (GlobeNewswire)
Aug-12-26 04:05PM	Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts (GlobeNewswire) +7.56%
08:30AM	Loading…
Aug-05-26 08:30AM	Acrivon Advances ACR-2316, a Potential First-in-Class WEE1/PKMYT1 Inhibitor, into Randomized Dose Expansion in its Ongoing Phase 1/2 Study (GlobeNewswire) +5.13%
Jul-21-26 04:30PM	Acrivon to Highlight the Power of its AP3 Platform for Streamlined, Pathway-Based Drug Discovery and Development with Oral and Poster Presentations at AACR D3 Conference (GlobeNewswire)
May-21-26 07:30AM	Acrivon Therapeutics to Present at TD Cowen's 7th Annual Oncology Innovation Summit (GlobeNewswire)
May-15-26 04:00PM	Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.81% -6.78%
May-13-26 04:10PM	Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts (GlobeNewswire)
Apr-17-26 04:00PM	Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities (GlobeNewswire) +6.59%
Apr-15-26 04:05PM	Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-19-26 07:21AM	Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
Mar-17-26 05:54PM	Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint Inhibitors (GlobeNewswire)
Mar-03-26 12:00PM	Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's Why (Zacks) +9.15%
11:47AM	Loading…
Feb-27-26 11:47AM	Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer (MarketBeat) -17.93%
Feb-24-26 08:00AM	Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference (GlobeNewswire)
Feb-23-26 08:00AM	Key Opinion Leader (KOL) Panel to Discuss Acrivon's ACR-368 Endometrial Cancer (EC) Trial during the 2026 European Society of Gynecological Oncology (ESGO) Congress (GlobeNewswire)
Feb-18-26 08:00AM	Acrivon Therapeutics Strengthens its Precision Medicine Therapeutics Capabilities with Launch of Internal CLIA-Certified Laboratory (GlobeNewswire)
Jan-28-26 09:15AM	Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer Treatment (PR Newswire)
Jan-23-26 08:11AM	Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress (GlobeNewswire)
Jan-08-26 02:02PM	Small-Cap Acrivon Highlights Tumor Shrinkage And Trial Progress Across Key Studies, Stock Falls (Benzinga) -34.58%
07:30AM	Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 (GlobeNewswire)
Jan-07-26 09:40AM	Is Humacyte, Inc. (HUMA) Outperforming Other Medical Stocks This Year? (Zacks)
Jan-06-26 07:30AM	Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast (GlobeNewswire) +31.44%
Dec-17-25 09:34AM	UPDATE -- Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast (GlobeNewswire)
07:30AM	Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates (GlobeNewswire)
Nov-29-25 01:26AM	H.C. Wainwright Initiates Coverage on Acrivon Therapeutics (ACRV) With "Buy" Rating and $19 PT (Insider Monkey)
Nov-13-25 04:10PM	Acrivon Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights (GlobeNewswire) -9.21% +8.21%
Nov-02-25 05:05AM	Analysts Predict Up to 550% Rally for These 2 Strong Buy Penny Stocks (TipRanks)
04:15PM	Loading…
Oct-22-25 04:15PM	Acrivon Therapeutics Highlights its Powerful Generative Phosphoproteomics AP3 Platform with Compelling Preclinical Data for ACR-2316 with Three Presentations at the Upcoming AACR-NCI-EORTC International Conference (GlobeNewswire)
Oct-01-25 04:30PM	Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-13-25 04:15PM	Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights (GlobeNewswire) +6.11%
May-17-25 12:30PM	Acrivon Therapeutics downgraded to Hold from Buy at JonesResearch (TipRanks)
May-14-25 04:10PM	Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights (GlobeNewswire)
May-05-25 09:55AM	Here's Why Acrivon Therapeutics, Inc. (ACRV) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Apr-28-25 12:23PM	Can Humana Beat Q1 Earnings Estimates on Growing Premiums? (Zacks) -5.49%
Apr-25-25 08:00AM	Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025 (GlobeNewswire) -17.59%
Apr-24-25 11:00AM	Universal Health to Report Q1 Earnings: Can it Surprise Wall Street? (Zacks)
Apr-23-25 01:41PM	HCA Healthcare to Report Q1 Earnings: Key Estimates to Note (Zacks)
01:28PM	Can Centene Beat Q1 Earnings Estimates on Growing Premiums? (Zacks)
Apr-22-25 11:19AM	Molina Healthcare to Report Q1 Earnings: Key Estimates to Watch (Zacks) +6.28%
Apr-14-25 09:35AM	Down -70.22% in 4 Weeks, Here's Why You Should You Buy the Dip in Acrivon Therapeutics, Inc. (ACRV) (Zacks) -7.41%
Apr-07-25 04:05PM	Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer (GlobeNewswire) -7.95%
Mar-28-25 12:00PM	Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's What You Should Know (Zacks) -11.11%
09:35AM	Here's Why Acrivon Therapeutics, Inc. (ACRV) is Poised for a Turnaround After Losing -52.81% in 4 Weeks (Zacks)
Mar-27-25 05:44PM	Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Mar-19-25 08:00AM	Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates (GlobeNewswire)
Feb-06-25 08:16AM	Acrivon Therapeutics announces FDA granted BDD for ACR-368 (TipRanks) -6.60%
04:54AM	FDA grants breakthrough designation for Acrivons endometrial cancer assay (Medical Device Network)
Feb-05-25 03:45PM	Acrivon Therapeutics (ACRV): AI-Powered Precision Oncology Gets FDA Breakthrough Status (Insider Monkey) +17.94%
08:00AM	Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer (GlobeNewswire)
Nov-13-24 07:00AM	Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights (GlobeNewswire) -5.48%
Oct-17-24 08:00AM	Acrivon Therapeutics to Present Data Demonstrating Deployment of its AP3 Platform for Streamlined Drug Discovery and Clinical Development at Two Scientific Conferences - Human Proteome Organization World Congress and EORTC-NCI-AACR Symposium (GlobeNewswire)
Oct-16-24 04:00PM	Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-12-24 08:28AM	Acrivon Therapeutics Launches Phase 1 Cancer Trial, Advances Oncology Pipeline (TipRanks)
Oct-11-24 08:00AM	Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity (GlobeNewswire)
Sep-14-24 03:10AM	Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis (GlobeNewswire)
Sep-10-24 08:00AM	Acrivon Therapeutics to Present at the Cantor Global Healthcare Conference (GlobeNewswire) +8.61%
Sep-09-24 07:00AM	Acrivon Therapeutics to Host Virtual Investor Event to Review Positive Phase 2 Clinical Data of ACR-368 Presented at ESMO and Pipeline Progress, Including Clinical Candidate ACR-2316 (GlobeNewswire)
Aug-15-24 09:40AM	Are Medical Stocks Lagging Acrivon Therapeutics, Inc. (ACRV) This Year? (Zacks)
Aug-13-24 08:00AM	Acrivon Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
Jun-21-24 09:40AM	Is Acrivon Therapeutics, Inc. (ACRV) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jun-05-24 09:40AM	Is Acrivon Therapeutics, Inc. (ACRV) Outperforming Other Medical Stocks This Year? (Zacks)
May-29-24 08:00AM	Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-28-24 09:47AM	Here's Why You Should Buy Acrivon Therapeutics (ACRV) Stock (Zacks)
May-20-24 09:40AM	Has Acrivon Therapeutics, Inc. (ACRV) Outpaced Other Medical Stocks This Year? (Zacks)
May-14-24 01:54PM	ACRV Stock Earnings: Acrivon Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
08:00AM	Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
May-10-24 08:50AM	Is a Surprise Coming for Acrivon Therapeutics (ACRV) This Earnings Season? (Zacks) +7.74%
Apr-29-24 07:08AM	Ladenburg Thalmann Downgrades Acrivon Therapeutics to Neutral (MT Newswires) +18.20%
Apr-24-24 04:01PM	Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event (GlobeNewswire) -10.84%
Apr-16-24 08:01PM	Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316 (GlobeNewswire) +9.19%
Apr-10-24 08:00AM	Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistance Mechanisms to ACR-368 (GlobeNewswire) +8.00%
Apr-09-24 10:32AM	ACRV Stock Jumps 55% as Acrivon Therapeutics Gets $130 Million Boost (InvestorPlace) +62.77%
07:00AM	Acrivon Therapeutics Announces $130 Million Private Placement Financing (GlobeNewswire)
Mar-30-24 05:31AM	Acrivon Therapeutics Inc (ACRV) Reports Increased Annual Loss: A Detailed Look Against Analyst ... (GuruFocus.com)
Mar-28-24 12:52PM	ACRV Stock Earnings: Acrivon Therapeutics Misses EPS for Q4 2023 (InvestorPlace) +10.60%
08:00AM	Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights (GlobeNewswire)
Mar-05-24 04:30PM	Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316 (GlobeNewswire)
Mar-04-24 08:00AM	Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of Directors (GlobeNewswire) -11.40%
Feb-27-24 08:00AM	Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care Conference (GlobeNewswire) +22.07%
Feb-08-24 08:00AM	Acrivon Therapeutics Appoints Seasoned Industry Executive Ivana Magov evi -Liebisch, Ph.D., J.D., to Board of Directors (GlobeNewswire)
Feb-06-24 08:00AM	Acrivon Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-12-24 04:00PM	Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.31%
Jan-04-24 08:00AM	Acrivon Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -6.63%
Jan-03-24 08:00AM	Acrivon Therapeutics Appoints Jean-Marie Cuillerot, M.D., as Chief Medical Officer (GlobeNewswire)
Nov-28-23 08:00AM	Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Ovarian Cancer (GlobeNewswire)
Nov-21-23 08:00AM	Acrivon Therapeutics to Present at the Piper Sandler Annual Healthcare Conference (GlobeNewswire) -9.02%
08:00AM	Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-09-23 08:01AM	Acrivon Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights (GlobeNewswire) -19.19%
Oct-16-23 08:00AM	Acrivon Therapeutics Presents Data Demonstrating Capabilities of its AP3 Platform and ACR-368 OncoSignature Assay for Patient Responder Identification at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Sep-28-23 04:05PM	Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-19-23 04:32PM	Acrivon Therapeutics to Highlight its ACR-368 OncoSignature Test, Used in Ongoing Phase 2 Study to Treat Patients Based on Predicted Sensitivity to Monotherapy with its CHK1/2 Inhibitor ACR-368, at the Upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Sep-05-23 04:05PM	Acrivon Therapeutics Announces ACR-2316, a Novel Dual WEE1 and PKMYT1 Inhibitor Development Candidate, Designed Using Acrivons AP3 Platform to Achieve Potent Single Agent Activity, as Demonstrated in Preclinical Studies (GlobeNewswire)
Aug-30-23 08:00AM	Acrivon Therapeutics to Participate in Two Investor Conferences in September (GlobeNewswire)
Aug-17-23 04:00PM	Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-11-23 07:00AM	Acrivon Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights (GlobeNewswire) +6.81%
Aug-08-23 12:38PM	Q2 2023 Akoya Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)
Jul-20-23 08:00AM	Acrivon Therapeutics Announces the Appointment of Adam Levy, Ph.D., M.B.A., Experienced Biotech Investor Relations and Strategy Executive, to Senior Vice President and Head, Investor Relations and Corporate Affairs (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Miller Mary	Chief Legal Officer	Oct 22 '26	Sale	1.84	513	944	81,202	Oct 26 04:03 PM
Miller Mary	Chief Legal Officer	Oct 05 '26	Sale	1.99	294	585	81,715	Oct 07 05:02 PM
Blume-Jensen Peter	President and CEO	Aug 25 '26	Sale	2.21	14,036	30,969	2,230,052	Aug 27 04:14 PM
Peter Blume-Jensen	Officer	Aug 25 '26	Proposed Sale	2.18	14,036	30,598		Aug 25 08:40 PM
Peterson Katharine	Chief Accounting Officer	Aug 18 '26	Sale	2.01	101	203	18,033	Aug 20 04:10 PM
Miller Mary	Chief Legal Officer	Aug 18 '26	Sale	2.01	185	372	82,009	Aug 20 04:09 PM
Gamelin Erick	Chief Development Officer	Aug 18 '26	Sale	2.01	400	804	52,592	Aug 20 04:08 PM
Devroe Eric	Chief Operating Officer	Aug 18 '26	Sale	2.01	604	1,214	146,349	Aug 20 04:07 PM
Blume-Jensen Peter	President and CEO	Aug 18 '26	Sale	2.01	1,229	2,470	2,244,088	Aug 20 04:07 PM
Blume-Jensen Peter	President and CEO	Aug 18 '26	Sale	2.01	484	973	385,859	Aug 20 04:07 PM
Levy Adam D.	Chief Financial Officer	Aug 04 '26	Sale	1.57	1,142	1,793	66,008	Aug 06 04:34 PM
Miller Mary	Chief Legal Officer	Jul 21 '26	Sale	1.76	573	1,008	82,194	Jul 23 04:28 PM
Blume-Jensen Peter	President and CEO	Jan 14 '26	Buy	1.68	49,000	82,124	2,095,771	Jan 16 04:02 PM
Levy Adam D.	Chief Financial Officer	Jan 14 '26	Buy	1.70	8,832	14,999	20,983	Jan 16 04:01 PM
Devroe Eric	Chief Operating Officer	Jan 13 '26	Buy	1.72	10,000	17,218	75,308	Jan 15 04:38 PM

Acrivon Therapeutics, Inc. develops drugs for clinical treatment. Its unique precision medicine platform is Acrivon Predictive Precision Proteomics (AP3). AP3 is used to generate proprietary OncoSignature companion diagnostics to identify patients who will benefit from the medicine. The company was founded by Peter Blume-Jensen and Kristina Masson in 2018 and is headquartered in Watertown, MA.

Ph.D.Dr. Peter Blume-Jensen M.D.

Ph.D.Ms. Kristina Masson M.B.A.

Chief Operating OfficerDr. Eric J. Devroe Ph.D.

Ph.D.Dr. Adam D. Levy M.B.A.

Vice President of Finance & AccountingMs. Katharine Peterson CPA

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ACRV

Acrivon Therapeutics Inc

Upgrade your Finviz experience